Limited data about biomarkers are available to predict the outcomes of targeted therapy in metastatic renal cell carcinoma (mRCC). Circulating cell-free DNA (CFD) is elevated in various cancers.
We performed a prospective study of patients with mRCC who received targeted therapy in the Soroka Medical Center between 2013 and 2015.
